14-Jan-2025
Cautious Hold on Alnylam Pharma Amid Uncertain Projections and Awaited Pipeline Progress
TipRanks (Wed, 15-Jan 2:02 AM ET)
Alnylam Pharma (ALNY) Gets a Buy from Bernstein
TipRanks (Tue, 14-Jan 6:31 AM ET)
Balanced Hold Rating on Alnylam Pharma Amid Promising Growth and Uncertainties
TipRanks (Mon, 13-Jan 2:56 PM ET)
Strong Growth Prospects and Financial Performance Drive Buy Rating for Alnylam Pharma
TipRanks (Mon, 13-Jan 11:25 AM ET)
Piper Sandler Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
TipRanks (Mon, 13-Jan 8:56 AM ET)
Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TipRanks (Mon, 13-Jan 6:55 AM ET)
Alnylam Pharma’s Strong Revenue Performance and Growth Potential Justifies ‘Buy’ Rating
TipRanks (Mon, 13-Jan 6:46 AM ET)
Alnylam Pharma’s Strong Financial Performance and Growth Prospects Justify Buy Rating
TipRanks (Mon, 13-Jan 6:16 AM ET)
Alnylam Pharma: Strong Financial Performance and Promising Growth Prospects
TipRanks (Mon, 13-Jan 5:35 AM ET)
Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y
Seeking Alpha News (Mon, 13-Jan 2:26 AM ET)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Alnylam Pharmaceuticals trades on the NASDAQ stock market under the symbol ALNY.
As of January 14, 2025, ALNY stock price declined to $240.51 with 719,481 million shares trading.
ALNY has a beta of 0.89, meaning it tends to be less sensitive to market movements. ALNY has a correlation of 0.04 to the broad based SPY ETF.
ALNY has a market cap of $31.02 billion. This is considered a Large Cap stock.
Last quarter Alnylam Pharmaceuticals reported $501 million in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-32 million and exceeded earnings estimates by $.43.
In the last 3 years, ALNY traded as high as $304.39 and as low as $117.58.
The top ETF exchange traded funds that ALNY belongs to (by Net Assets): VTI, VO, VXF, VUG, VOT.
ALNY has outperformed the market in the last year with a price return of +24.4% while the SPY ETF gained +23.6%. However, in the short term, ALNY had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.1% vs 0.0% return in SPY. But in the last 2 weeks, ALNY shares have fared better than the market returning +2.2% compared to SPY -0.7%.
ALNY support price is $252.10 and resistance is $264.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALNY shares will trade within this expected range on the day.